11 active not recruiting, 9 recruiting, 2 terminated, 1 completed. 24 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 24 | Active not recruiting 11, Recruiting 9, Terminated 2, Completed 1, Withdrawn 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow apalutamide: new trials by email Literature Review of apalutamide trials Research Report on apalutamide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer Abiraterone, Apalutamide, Enzalutamide or Darolutamide (ARPI therapy) (per standard of care) therapy - Prostate Cancer, mHSPC | Phase 3 | Recruiting | University College, London | 1500 | 2026-08-28 | 2026-11-04 |
| Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial. Apalutamide (Erleada™) 60 mg or 240 mg tablets, Docetaxel - Metastatic Hormone-sensitive Prostate Cancer | Phase 3 | Recruiting | Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD | 320 | 2026-06-05 | 2026-06-17 |
| AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]), Cabazitaxel, Abiraterone - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Recruiting | AstraZeneca | 670 | 2026-05-04 | 2026-10-19 |
| Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial Androgen Therapy, Apalutamide, Docetaxel - Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 1260 | 2025-12-01 | 2026-11-03 |
| Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response Abiraterone, Enzalutamide, Apalutamide - Prostate Cancer (Adenocarcinoma) | Phase 3 | Recruiting | Canadian Cancer Trials Group | 830 | 2025-05-28 | 2026-07-14 |
| Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders) 177Lu-PMSA-617, Standard of Care - Prostate Cancer Metastatic | Phase 3 | Recruiting | UNICANCER | 500 | 2024-09-12 | 2024-12-20 |
| PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer. Apalutamide, Androgen Deprivation Therapy - Androgen Axis Suppression, Prostatectomy | Phase 3 | Recruiting | M.D. Anderson Cancer Center | 120 | 2024-09-10 | 2026-07-22 |
| A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC Apalutamide, Androgen-deprivation Therapy (ADT) - Metastatic Castrate-sensitive Prostate Cancer | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 420 | 2023-08-31 | 2026-09-25 |
| Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease - Prostate Cancer, Oligometastasis | Phase 2 / Phase 3 | Active not recruiting | VA Office of Research and Development | 378 | 2021-07-01 | 2026-11-05 |
| Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial Apalutamide, Bicalutamide, Biospecimen Collection - Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8 | Phase 3 | Active not recruiting | NRG Oncology | 2753 | 2021-01-21 | 2026-08-17 |
| A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer Radiotherapy, LHRHa, Apalutamide - Prostatic Neoplasms | Phase 3 | Active not recruiting | Janssen Pharmaceutica N.V., Belgium | 691 | 2020-11-12 | 2026-11-03 |
| Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging 3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography - Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 804 | 2020-10-08 | 2026-11-13 |
| Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer Apalutamide, Enzalutamide - Prostate Cancer | Phase 3 | Terminated | Chinese University of Hong Kong | 74 | 2020-07-20 | 2026-10-27 |
| Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT Prednisone, Apalutamide, Abiraterone Acetate - Prostate Cancer | Phase 3 | Terminated | Dana-Farber Cancer Institute | 12 | 2020-04-20 | 2024-09-19 |
| Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial Apalutamide, Biospecimen Collection, Bone Scan - Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8 | Phase 3 | Active not recruiting | NRG Oncology | 586 | 2020-04-16 | 2026-11-18 |
| Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer Radiation Therapy, Apalutamide, Luteinising Hormone Releasing Hormone analog agonist (LHRHa) - Prostate Cancer | Phase 3 | Withdrawn | European Organisation for Research and Treatment of Cancer - EORTC | 2020-03-10 | 2020-08-17 | |
| Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy Apalutamide, Salvage radiotherapy (SRT), Luteinising Hormone Releasing Hormone agonist (LHRHa) - Prostate Cancer | Phase 3 | Active not recruiting | UNICANCER | 490 | 2020-01-09 | 2025-07-30 |
| A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy Apalutamide, Androgen Deprivation Therapy (ADT), Placebo - Prostatic Neoplasms | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 2517 | 2019-06-11 | 2026-11-03 |
| ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer Enzalutamide Oral Capsule, Abiraterone Oral Tablet, Carboplatin - Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase 3 | Recruiting | Karolinska Institutet | 750 | 2019-02-01 | 2025-04-09 |
| A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer Apalutamide, LHRH Analogue, Abiraterone Acetate - Prostate Cancer | Phase 3 | Completed | Alliance Foundation Trials, LLC. | 503 | 2017-03-06 | 2026-11-09 |
Showing 20 of 24. Sign in to see all of them.
Prostatic Neoplasms (21) · Neoplasm Metastasis (2) · Adenocarcinoma (1) · Genital Diseases, Male (1) · Patient Preference (1) · Prostatic Diseases (1)
Aragon Pharmaceuticals, Inc. (4) · Janssen Research & Development, LLC (2) · NRG Oncology (2) · UNICANCER (2) · Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD (1) · Alliance Foundation Trials, LLC. (1) · Alliance for Clinical Trials in Oncology (1) · AstraZeneca (1) · Canadian Cancer Trials Group (1) · Chinese University of Hong Kong (1) · Dana-Farber Cancer Institute (1) · ECOG-ACRIN Cancer Research Group (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Janssen Pharmaceutica N.V., Belgium (1) · Karolinska Institutet (1)
United States (17) · Canada (10) · France (10) · Germany (9) · Spain (8) · Australia (7) · Brazil (7) · Poland (7) · United Kingdom (7) · Belgium (6) · Mexico (6) · Russia (6) · South Korea (6) · Sweden (6) · Czechia (5)
Abhishek Solanki, MD MS (1) · Alexandra Sokolova (1) · Ananya Choudhury, Professor (1) · Anthony D'Amico, MD, PhD (1) · Ashkan Mortezavi, MD, PhD (1) · Chi Fai NG, MD (1) · Evanthia Evanthia Galanis, MD (1) · Gilles Crehange (1) · Jan Oldenburg, Professor (1) · Johan Lindberg, PhD (1)
PMID 32878613, PMID 37951974, PMID 38421243, PMID 39163505, PMID 29420164, PMID 30213449, PMID 31150574, PMID 31578173, PMID 31980408, PMID 32586393, PMID 33914595, PMID 34039013, PMID 34600602, PMID 34797506, PMID 35213039, PMID 35317973, PMID 36082554, PMID 36209239, PMID 37071764, PMID 37708629, PMID 38261983, PMID 38421252, PMID 38940282, PMID 39058790, PMID 39164518, PMID 39405060, PMID 39889245, PMID 40132221, PMID 40263079, PMID 40645505, PMID 42223077, PMID 42616151, PMID 42728112
2023 (4), 2015 (2), U10CA180868 (2), 2014 (1), 2017 (1), 2018 (1), 2019 (1), 2025 (1), I01CX002277 (1), U10CA180820 (1)